What\'s known
=============

1.  As the incidence of diabetes mellitus (DM), a risk factor for pulmonary tuberculosis (PTB), has been gradually increasing worldwide in high-burden TB countries, it has been increasingly observed in new cases of PTB. However, few data have been collected regarding clinical and laboratory parameters, response to therapy and development of anti-TB drug resistance in PTB patients with DM and PTB patients without DM for comparison of these patient populations.

What\'s new
===========

1.  Diabetes mellitus was observed in 16.3% of new patients with PTB. Mycobacterium burden, sputum-culture conversion rate, multidrug-resistant tuberculosis rate, treatment outcomes and relapse rates were similar in PTB patients with DM and those without DM. The findings suggest that plasma glucose should be monitored in PTB patients and a similar treatment regimen should be prescribed to PTB patients with DM and those without DM.

Introduction
============

According to the 2011, World Health Organization (WHO) report, tuberculosis (TB) and human immunodeficiency virus (HIV) are two of the top five causes of death in developing countries [@b1]. Although the estimated incidence of TB in Thailand was 124 per 100,000 populations in 2011, the estimated incidence of TB and HIV coinfection decreased in the same year [@b2]. At the same time, the incidence of diabetes mellitus (DM) has been increasing worldwide, having increased from 153 million to 347 million between 1980 and 2008, because of changes in diet, physical activity, body mass index and ageing patterns [@b3],[@b4]. Previous reports found that patients with DM were two to eight times at higher risk for development of active TB and at approximately three times higher risk for development of pulmonary TB (PTB) as compared with patients without DM [@b5]--[@b8]. DM patients with a haemoglobin A1C concentration of \> 7 mmol/mol are especially at risk, as elevated A1C concentration is associated with decreased phagocytic activity and T-cell function resulting in impaired cell-mediated immunity [@b8],[@b9]. This phenomenon reflects the fact that cell-mediated immunity plays a pivotal role in defence against intracellular organisms, particularly *Mycobacterium tuberculosis* [@b7]. Nevertheless, the occurrence of PTB rather than extra-PTB in patients with DM has been attributed to decreased activation of alveolar macrophages [@b10].

Previous studies found that TB patients with DM experienced higher rates of treatment failure and fatality than those without DM [@b11]--[@b15]. These studies, which included patients experiencing different levels of TB severity and HIV coinfection, indicated that coinfection with these diseases might be a possible risk factor for mortality in DM patients [@b16]. However, few data have been collected regarding clinical presentation, severity of disease, response to therapy and development of anti-TB drug resistance in PTB patients with DM and PTB patients without DM. To fill this research gap, this prospective study aimed to determine the incidence of DM in newly diagnosed cases of PTB and to compare the clinical and laboratory parameters, extent of drug susceptibility and treatment outcomes between PTB patients with DM and PTB patients without DM who presented at the Queen Savang Vadhana Memorial Hospital and the Chonburi Hospital, Chonburi province, Thailand between April 2010 and July 2012.

Methods
=======

Study site and population
-------------------------

This study was approved by the Ethics Committee of the Faculty of Tropical Medicine, Mahidol University in Bangkok; the Queen Savang Vadhana Memorial Hospital in Chonburi province; and the Chonburi Hospital in Chonburi province, Thailand. Written informed consent was obtained from all patients. A prospective study had been conducted between April 2010 and July 2012 at the Queen Savang Vadhana Memorial Hospital and the Chonburi Hospital. All subjects met the subject inclusion criteria of: (i) age ≥ 15 years; (ii) presence of ≥ 2 pulmonary or constitutional symptoms, including cough, dyspnoea, chest pain, haemoptysis, fever, fatigue, malaise, weight loss and/or night sweats; (iii) new diagnosis of PTB according to the 2010 WHO guidelines for TB [@b17]; and (iv) a sputum culture positive for *M. tuberculosis*. PTB patients were defined as patients with abnormal chest radiographic findings of the reticular, interstitial, nodular infiltrate, or the chest cavity and at least one of three sputum smears testing positive for acid-fast bacilli (AFB) [@b17]. New cases of PTB were defined as PTB patients who had never received treatment for TB or patients who had taken any anti-TB drug for \< 1 month [@b17]. None of the subjects met the exclusion criteria of: (i) culture negative for mycobacterium, (ii) culture positive for non-TB mycobacterium, (iii) HIV infection, or (iv) no data were available regarding DM or HIV status.

Data regarding patient demographic characteristics and clinical and laboratory parameters were collected and entered into a predefined case record form. All patients were placed under management and prescribed appropriate anti-TB regimens based on decisions made by clinicians at the Queen Savang Vadhana Memorial Hospital and the Chonburi Hospital. Family-based directly observed treatment, defined as the taking of prescribed anti-TB medications in the presence of family members, was incorporated into the overall treatment regimen to improve patient adherence to treatment and prevent the development of drug resistance. All patients were regularly followed up at intervals of 1--4 weeks to assess overall treatment progress as well as document adverse drug events to anti-TB medications and drug adherence until completion of treatment. Non-adherence was defined as the inability to take any prescribed anti-TB medications for at least 7 days [@b18].

Diagnosis of DM
---------------

The criteria used to diagnose DM were the 2010 American Diabetes Association criteria [@b19] of: (i) fasting plasma glucose levels ≥ 126 mg/dl after fasting for at least 8 h on two occasions and/or (ii) random plasma glucose levels ≥ 200 mg/dl. Patients without DM were defined as patients who did not fulfil the criteria for DM.

Sputum smear and culture for mycobacterium
------------------------------------------

Sputum samples were collected for AFB smears and identification of mycobacterium prior to treatment and at months 2 and 5 of treatment. After collection on 3 different days in sterile, disposable, leak-proof and laboratory-approved containers, three early-morning expectorated sputum samples were sent to the Central Laboratory Unit of the Queen Savang Vadhana Memorial Hospital and the Chonburi Hospital for AFB smears using the Ziehl--Neelsen staining, as described elsewhere [@b20]. The results of the AFB smears were interpreted using the 1998 WHO Laboratory Services in TB Control Grading System, according to which AFB \< 1+ was defined as 1--9 AFB per 100 oil immersion field (OIF), 1+ as 10--99 AFB per 100 OIF, 2 + as 1--10 AFB per OIF and 3+ as \> 10 AFB per OIF [@b20].

While being maintained at 4--5° C, the sputum sample of each patient found to have the highest AFB grading was transported at each time point to the National Tuberculosis Reference Laboratory of Thailand for mycobacterium culture. The mycobacterium in sputum samples was cultured and drug susceptibility testing was conducted using Lowenstein--Jensen solid medium and liquid medium BACTEC MGIT 960 (Becton Dickinson, MD) according to the manufacturer\'s instruction. Detection of growth on either one of the two culture media was considered a positive culture.

Sample size calculation
-----------------------

The sample size was estimated based on previous studies conducted in tropical countries that had found that 10--30% of PTB cases examined also had DM [@b21],[@b22]. In this study, the proportion of PTB patients with DM was estimated to be 15%, with a 95% confidence interval, and the precision to be within 5% of the true value and an estimated 10% loss to follow up. A sample size of at least 218 PTB patients was required in our study. In order to compare clinical and laboratory parameters and treatment outcomes between PTB patients with and without DM, data regarding treatment failure were analysed for calculation of sample size. A previous study conducted in Indonesia found that the proportion of PTB patients with and without DM with a positive sputum culture at 6 months was 22% and 6%, respectively [@b23]. Based on these data, the required sample size ratio of PTB patients with DM to PTB patients without DM was estimated at 1:5. To be able to reject the null hypothesis that the failure rates for PTB patients with and without DM are equal at a probability (power) of 0.8 and an alpha level of 0.05, a sample of at least 216 patients that included at least 36 PTB patients with DM and 180 PTB patients without DM needed to be studied. Thus, the minimum sample size was determined to be 218 patients.

Statistical analysis
--------------------

Data were entered into Microsoft Excel and analysed using the Statistical Package for the Social Sciences for Windows version 18.0 (SPSS Inc., Chicago, IL). Categorical variables were summarised as frequencies and percentages, and then analysed using the χ^2^ test or the Fisher\'s exact test where appropriate. Stratified analysis was performed using the Mantel--Haenszel method for binary outcomes to control for potential confounding effect of age. Continuous variables were tested for normality using the Kolmogorov--Smirnov test. Variables with a non-normal distribution were summarised by calculation of their median and interquartile range (IQR) values and compared using the Mann--Whitney *U*-test for two-group comparison. All tests for significance were two-sided and a p \< 0.05 was considered an indication of statistical significance.

Results
=======

A total of 310 new patients with PTB were diagnosed and subsequently managed at the Queen Savang Vadhana Memorial Hospital and the Chonburi Hospital between April 2010 and July 2012. Of these 310 patients, underlying medical illness was observed in 117 (37.9%), including DM (51 patients, 43.6%), HIV infection (33 patients, 28.2%), coronary artery disease (30 patients, 25.6%), liver disease (21 patients, 17.9%), chronic obstructive pulmonary disease (8 patients, 6.8%) and rheumatoid arthritis (4 patients, 3.4%). Testing for presence of mycobacterium from sputum samples revealed that 18 (5.8%) patients with cultures positive for non-tuberculous mycobacterium, 19 (6.1%) with cultures negative for mycobacterium and the remaining 273 (88.1%) with cultures positive for *M. tuberculosis*. Of these 273 patients, no data regarding DM or HIV status were available for 13, while data regarding a positive result from serological testing for HIV were available for 33.

Based on review of the data collected thus far, 227 new patients with a positive PTB culture were identified and determined eligible for study participation. Of these 227 patients, 37 (16.3%) were also diagnosed with DM and 190 (83.7%) were not diagnosed with DM (Figure[1](#fig01){ref-type="fig"}). Among the 37 PTB patients with DM, 26 (70.3%) had been diagnosed with DM prior to being diagnosed with PTB while 11 (29.7%) had developed DM at PTB diagnosis. Regarding the management of DM, 33 (89.2%) PTB patients with DM had undergone administration of hypoglycaemic drugs, including biguanide (28 patients, 84.8%), sulfonylurea (23 patients, 69.7%), insulin (5 patients, 15.2%), thiazolidinedione (4 patients, 12.1%) and dipeptidyl peptidase IV inhibitors (1 patient, 3.0%), while four patients (11.8%) had undergone solely dietary management of DM.

![Flow diagram of the study](ijcp0067-1199-f1){#fig01}

Baseline characteristics and clinical and laboratory parameters of PTB patients with and without DM
---------------------------------------------------------------------------------------------------

The baseline characteristics of PTB patients with and without DM are presented in Table[1](#tbl1){ref-type="table"}. While the data regarding sex (i.e. proportion of males), marital status, smoking history, alcohol consumption and presence of extra-PTB were similar for the two patient groups, the data regarding age (median 51.0 years, IQR: 42.5--60.5 vs. median 36.0, IQR: 27.8--48.0 years, respectively), proportion ≥ 50 years, and proportion either illiterate or with only a primary school education were significantly higher in the group of PTB patients with DM than that of PTB patients without DM (p \< 0.001).

###### 

Baseline characteristics and clinical and laboratory parameters of new cases of culture-positive pulmonary tuberculosis with and without diabetes mellitus

  Characteristic                                 *n*   PTB patients with DM   PTB patients without DM   Crude OR (95% CI)   p-Value                              
  ---------------------------------------------- ----- ---------------------- ------------------------- ------------------- ------------ ----------------------- ----------
  **Baseline characteristic**                                                                                                                                    
   Age ≥ 50 years                                227   37                     20 (54.0)                 190                 44 (23.1)    3.904 (1.883--8.094)    \< 0.001
   Male sex                                      227   37                     28 (75.7)                 190                 143 (75.3)   1.023 (0.450--2.322)    1.000
   Married                                       227   37                     23 (62.2)                 190                 125 (65.8)   0.854 (0.412--1.771)    0.814
   Illiterate or primary school education only   209   33                     25 (75.8)                 176                 95 (54.0)    2.664 (1.139--6.231)    0.033
   Smoking history                               225   36                     24 (66.7)                 189                 129 (68.3)   0.930 (0.436--1.984)    1.000
   Alcohol consumption                           226   36                     26 (72.2)                 190                 137 (72.1)   1.006 (0.454--2.228)    1.000
   Extra-pulmonary tuberculosis                  227   37                     1 (2.7)                   190                 5 (2.6)      1.028 (0.117--9.060)    1.000
  **Clinical presentation**                                                                                                                                      
   Cough                                         225   36                     30 (83.3)                 189                 178 (94.2)   0.309 (0.106--0.898)    0.036
   Dyspnoea                                      225   36                     26 (72.2)                 189                 124 (65.5)   1.363 (0.619--2.999)    0.563
   Anorexia                                      225   36                     24 (66.7)                 189                 87 (46.0)    2.345 (1.108--4.962)    0.037
   Fever                                         225   36                     22 (61.1)                 189                 135 (71.4)   0.629 (0.300--1.318)    0.300
   Chest pain                                    225   36                     17 (47.2)                 189                 107 (56.6)   0.686 (0.336--1.401)    0.392
   Haemoptysis                                   225   36                     16 (44.4)                 189                 65 (34.4)    1.526 (0.741--3.144)    0.336
   Body weight decrease \> 5%                    196   29                     22 (75.9)                 167                 115 (68.9)   1.421 (0.571--3.536)    0.590
  **Laboratory parameter**                                                                                                                                       
   Haemoglobin level \< 12 g/dl                  138   22                     15 (68.2)                 116                 64 (55.2)    1.741 (0.661--4.588)    0.370
   WBC count \> 10 × 10^3^/μl                    138   22                     9 (40.9)                  116                 78 (67.2)    0.337 (0.133--0.858)    0.035
   Sodium level \< 135 mmol/l                    85    14                     10 (71.4)                 71                  35 (49.3)    2.571 (0.737--8.970)    0.221
   Creatinine level \> 1.2 mg/dl                 109   17                     3 (17.8)                  92                  4 (4.3)      4.714 (0.952--23.342)   0.075
   Albumin level \< 3.5 g/dl                     153   22                     12 (54.5)                 131                 76 (58.0)    0.868 (0.350--2.153)    0.943
   AST level \> 40 U/l                           157   23                     5 (21.7)                  134                 34 (25.4)    0.817 (0.282--2.369)    0.911
   ALT level \> 40 U/l                           158   24                     6 (25.0)                  134                 26 (19.4)    1.385 (0.500--3.833)    0.582
   Cavity on chest radiograph                    201   34                     12 (35.3)                 167                 55 (32.9)    1.111 (0.512--2.408)    0.947
   Sputum AFB grading 3+                         227   37                     9 (24.3)                  190                 44 (23.2)    1.067 (0.468--2.429)    1.000

PTB, pulmonary tuberculosis; DM, diabetes mellitus; OR, odds ratio; CI, confidence interval; IQR, interquartile range; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AFB, acid-fast bacilli.

Regarding clinical parameters, cough was the most common presenting symptom of all PTB patients, but the proportion of patients presenting with cough was significantly lower in PTB patients with DM than those without DM. In contrast, the proportion of patients presenting with anorexia was significantly higher in PTB patients with DM than those without DM. The prevalence of other presenting symptoms and signs, including dyspnoea, fever, chest pain, haemoptysis and body weight decrease of \> 5% from baseline were similar in both groups (Table[1](#tbl1){ref-type="table"}).

Regarding laboratory parameters, the only parameter that significantly differed between the two groups was the proportion of patients with white blood cell counts \> 10 × 10^3^/μl, which was significantly lower in PTB patients with DM than those without DM. The proportions of patients within each group for which specific laboratory parameter results had been obtained, including haemoglobin level \> 12 g/dl, serum sodium level \< 135 mmol/l, serum creatinine level \> 1.2 mg/dl, serum albumin level \< 3.5 g/dl, aspartate aminotransferase level \> 40 U/l, alanine aminotransferase level \> 40 U/l, presence of cavity on chest radiograph and sputum AFB grading 3+, were similar (Table[1](#tbl1){ref-type="table"}).

Management, drug susceptibility and treatment outcomes in PTB patients with and without DM
------------------------------------------------------------------------------------------

The majority of all PTB patients had undergone a standard treatment regimen of anti-TB medication that included 2 months of isoniazid, rifampicin, ethambutol and pyrazinamide administration during the intensive phase, followed by 4 months of isoniazid and rifampicin administration during the continuation phase. The proportions of patients who had undergone a standard treatment regimen of anti-TB medication and the proportion that had experienced non-adherence and/or adverse drug events were similar in both groups, as was the median duration of treatment during both the intensive and continuation phases (Table[2](#tbl2){ref-type="table"}). The adverse drug events experienced by patients in both groups had been rash (93/205 patients, 45.4%), peripheral neuropathy (75/205 patients, 36.6%), visual disturbance (41/205 patients, 20.0%), fatigue (22/205 patients, 10.7%), cholestasis (6/205 patients, 2.9%) and hepatitis (4/205 patients, 2.0%).

###### 

Management and treatment outcomes of new cases of culture-positive pulmonary tuberculosis with and without diabetes mellitus

  Characteristic               *n*   PTB patients with DM   PTB patients without DM   Crude OR (95% CI)   p-Value                                        
  ---------------------------- ----- ---------------------- ------------------------- ------------------- ---------------------- ----------------------- -------
  **Management**                                                                                                                                         
   Standard regimen                                                                                                                                      
    Intensive phase            227   37                     35 (94.6)                 190                 188 (98.9)             0.186 (0.025--1.366)    0.125
    Continuation phase         206   35                     32 (91.4)                 171                 168 (98.2)             0.190 (0.037--0.986)    0.063
   Duration, median (IQR)                                                                                                                                
    Intensive phase, days      226   36                     62.5 (54.2--70.0)         190                 62.0 (53.0--73.0)      −                       0.632
    Continuation phase, days   200   33                     119.0 (109.0--139.0)      167                 120.0 (112.0--141.0)   −                       0.589
   Non-adherence                                                                                                                                         
    Intensive phase            224   36                     6 (16.7)                  188                 24 (12.8)              1.367 (0.515--3.625)    0.592
    Continuation phase         202   32                     10 (31.3)                 170                 62 (36.5)              0.792 (0.352--1.780)    0.715
   Adverse drug events                                                                                                                                   
    Intensive phase            190   32                     26 (81.3)                 158                 100 (63.3)             2.513 (0.977--6.465)    0.079
    Continuation phase         85    10                     8 (80.0)                  75                  38 (50.7)              3.895 (0.775--19.568)   0.100
  **Treatment outcome**                                                                                                                                  
   Sputum-culture conversion                                                                                                                             
    At month 2                 208   34                     29 (85.3)                 174                 146 (83.9)             1.112 (0.396--3.121)    1.000
    At month 5                 197   32                     30 (93.8)                 165                 161 (97.6)             0.373 (0.065--2.127)    0.252
   Treatment success           227   37                     30 (81.1)                 190                 156 (82.1)             0.934 (0.379--2.303)    1.000
    Cured                                                   21 (70.0)                                     116 (71.6)                                     
    Treatment completed                                     9 (30.0)                                      40 (28.4)                                      
   Death                       223   37                     2 (5.4)                   186                 4 (2.2)                2.600 (0.458--14.747)   0.260

PTB, pulmonary tuberculosis; DM, diabetes mellitus; OR, odds ratio; CI, confidence interval; IQR, interquartile range.

At PTB diagnosis, drug susceptibility testing revealed no significant difference in isoniazid resistance \[1/37 (2.7%) patients vs. 14/184 (7.8%) patients, p = 0.476\] and rifampicin resistance \[0/37 (0%) patients vs. 2/184 (1.1%) patients, p = 1.000\] between PTB patients with DM and those without DM, but none had ethambutol resistance in both groups. The presence of primary multidrug-resistant TB (MDR-TB) was similar between PTB patients with DM and those without DM \[0/37 (0%) patients vs. 2/184 (1.1%) patients, p = 1.000\]. At 2 months of treatment, the presence of isoniazid resistance \[0/33 (0%) patients vs. 4/173 (2.3%) patients, p = 1.000\] and rifampicin resistance \[0/33 (0%) patients vs. 1/173 (0.6%) patients, p = 1.000\] was similar between PTB patients with DM and those without DM, but none had ethambutol resistance in both groups. The presence of MDR-TB was similar between PTB patients with DM and those without DM \[0/33 (0%) patients vs. 1/173 (0.6%) patients, p = 1.000\]. At 5 months of treatment, the presence of isoniazid resistance \[0/31 (0%) patients vs. 2/165 (1.2%) patients, p = 1.000\], rifampicin resistance \[0/31 (0%) patients vs. 2/165 (1.2%) patients, p = 1.000\] and ethambutol resistance \[0/31 (0%) patients vs. 1/165 (0.6%) patients, p = 1.000\] was also similar between PTB patients with DM and those without DM. The presence of MDR-TB was similar between PTB patients with DM and those without DM \[0/31 (0%) patients vs. 2/165 (1.2%) patients, p = 1.000\].

The treatment outcomes evaluated were sputum-culture conversion rate; treatment success rate, which included consideration of cure rate and rate of patients who completed treatment according to the 2010 WHO Guidelines for TB [@b17]; and case fatality rate. The treatment outcomes of sputum-culture conversion rate at 2 months, sputum-culture conversion rate at 5 months, treatment success rate and case fatality rate were found to be similar for PTB patients with and without DM (Table[2](#tbl2){ref-type="table"}). Evaluation of other treatment outcomes described in the 2010 WHO Guidelines for TB [@b17] revealed that among the 37 PTB patients with DM, 2 (5.4%) patients had experienced treatment failure, 2 (5.4%) patients had defaulted and 1 (2.7%) patient had been observed to have transferred out. Among the 190 PTB patients without DM, 4 (2.1%) had experienced treatment failure, 19 (10.0%) had defaulted and 7 (3.7%) had been transferred out.

Among the group of 192 PTB patients who had experienced treatment success, which included 30 patients with DM and 162 patients without DM, 0 (0%) of patients with DM and only 1 (0.6%) patient without DM experienced relapse after completion of treatment for PTB. The median durations of follow up after completion of PTB treatment for patients with and without DM were 337.5 days (IQR: 247.5--431.0) and 359.0 days (IQR: 266.5--478.3), respectively, the difference between which did not reach a level of statistical significance (p = 0.333).

Comparison of PTB patients with and without DM after adjustment for age
-----------------------------------------------------------------------

Two previous studies reported that while type 2 DM mostly occurred in adults aged \> 40 years, the majority (88%) of patients with smear-positive PTB in the study samples had been aged 15--64 years [@b2],[@b4]. As analysis of the data collected in this study revealed the median age of PTB patients with and without DM to be 51.0 (IQR: 42.5--60.5) and 36.0 (27.8--48.0) years, respectively (p \< 0.001), the patients were stratified into two groups by age (\< 50 and ≥ 50 years) in order to control for confounding variables. Subsequent analysis revealed that baseline characteristics, including sex (i.e. proportion of males), marital status, education level, smoking history, alcohol consumption and incidence of extra-PTB, as well as clinical parameters, including presence of dyspnoea, fever, chest pain and body weight decrease \> 5%, were similar for both the groups. However, a significantly higher proportion of PTB patients with DM had presented with anorexia and haemoptysis, while a significantly higher proportion of PTB patients without DM had presented with cough. Despite these differences, the results of testing of laboratory parameters were similar for both groups (Table[3](#tbl3){ref-type="table"}), as was the proportion of patients who had undergone a standard treatment regimen of anti-TB medications and had experienced non-adherence and/or adverse drug events. Moreover, both the groups had undergone treatment regimens of a similar duration and had experienced similar treatment outcomes, including sputum-culture conversion rate, treatment success rate and case fatality rate, subsequent to completion of treatment (Table[4](#tbl4){ref-type="table"}).

###### 

Baseline characteristics and clinical and laboratory parameters of new cases of culture-positive pulmonary tuberculosis with and without diabetes mellitus after adjustment for age

  Characteristic                                 PTB patients \< 50 years   PTB patients ≥ 50 years   DM vs. non-DM patients (all ages)                                                                                          
  ---------------------------------------------- -------------------------- ------------------------- ----------------------------------- ------------ ------- ---- ----------- ---- ----------- ------- ----------------------- -------
  **Baseline characteristic**                                                                                                                                                                                                    
   Male sex                                      17                         17 (100)                  146                                 102 (69.9)   0.007   20   11 (55.0)   44   41 (93.2)   0.001   1.129 (0.492--2.594)    0.774
   Married                                       17                         9 (52.9)                  146                                 90 (61.6)    0.665   20   14 (70.0)   44   35 (79.5)   0.526   0.657 (0.303--1.425)    0.288
   Illiterate or primary school education only   15                         8 (53.3)                  135                                 61 (45.2)    0.743   18   17 (94.4)   41   34 (82.9)   0.414   1.742 (0.683--4.446)    0.245
   Smoking history                               16                         13 (81.3)                 145                                 91 (62.8)    0.233   20   11 (55.0)   44   38 (86.4)   0.010   1.306 (0.601--2.839)    0.501
   Alcohol consumption                           16                         14 (87.5)                 146                                 106 (72.6)   0.244   20   12 (60.0)   44   31 (70.5)   0.566   1.137 (0.490--2.638)    0.765
   Extra-pulmonary tuberculosis                  17                         0                         146                                 4 (2.7)      1.000   20   1 (5.0)     44   1 (2.3)     0.531   0.941 (0.088--10.094)   0.960
  **Clinical presentation**                                                                                                                                                                                                      
   Cough                                         17                         14 (82.4)                 145                                 137 (94.5)   0.093   19   16 (84.2)   44   41 (93.2)   0.355   0.324 (0.106--0.986)    0.047
   Dyspnoea                                      17                         11 (64.7)                 145                                 98 (67.6)    1.000   19   15 (78.9)   44   26 (59.1)   0.219   1.416 (0.638--3.142)    0.392
   Anorexia                                      17                         9 (52.9)                  145                                 66 (45.5)    0.746   19   15 (78.9)   44   21 (47.7)   0.043   2.148 (1.001--4.607)    0.050
   Fever                                         17                         10 (58.8)                 145                                 107 (73.8)   0.251   19   12 (63.2)   44   28 (63.6)   1.000   0.697 (0.326--1.489)    0.352
   Chest pain                                    17                         7 (41.2)                  145                                 88 (60.7)    0.199   19   10 (52.6)   44   19 (43.2)   0.678   0.789 (0.381--1.636)    0.525
   Haemoptysis                                   17                         11 (64.7)                 145                                 58 (40.0)    0.091   19   5 (26.3)    44   7 (15.9)    0.485   2.388 (1.061--5.376)    0.036
   Body weight decrease \> 5%                    14                         9 (63.4)                  135                                 95 (70.4)    0.761   15   13 (86.7)   32   20 (62.5)   0.170   1.420 (0.569--3.543)    0.452
  **Laboratory parameter**                                                                                                                                                                                                       
   Haemoglobin level \< 12 g/dl                  11                         6 (54.5)                  88                                  48 (54.5)    1.000   11   9 (81.8)    28   16 (57.1)   0.266   1.601 (0.599--4.274)    0.348
   WBC count \> 10 × 10^3^/μl                    11                         5 (45.5)                  88                                  63 (71.6)    0.094   11   4 (36.4)    28   15 (53.6)   0.541   0.399 (0.153--1.038)    0.059
   Sodium level \< 135 mmol/l                    7                          4 (57.1)                  52                                  22 (42.3)    0.688   7    6 (85.7)    19   13 (68.4)   0.629   2.112 (0.572--7.792)    0.262
   Creatinine level \> 1.2 mg/dl                 9                          0                         67                                  2 (3.0)      1.000   8    3 (37.5)    25   2 (8.0)     0.078   3.873 (0.710--21.131)   0.118
   Albumin level \< 3.5 g/dl                     10                         4 (40.0)                  102                                 55 (53.9)    0.513   12   8 (66.7)    29   21 (72.4)   0.721   0.649 (0.245--1.716)    0.383
   AST level \> 40 U/l                           11                         2 (18.2)                  104                                 23 (22.1)    1.000   12   3 (25.0)    30   11 (36.7)   0.719   0.665 (0.221--2.000)    0.468
   ALT level \> 40 U/l                           11                         3 (27.3)                  104                                 16 (15.4)    0.387   13   3 (23.1)    30   10 (33.3)   0.720   1.073 (0.382--3.016)    0.893
   Cavity on chest radiograph                    16                         7 (43.8)                  129                                 45 (34.9)    0.674   18   5 (27.8)    38   10 (26.3)   1.000   1.282 (0.572--2.870)    0.546
   Sputum AFB grading 3+                         17                         5 (29.4)                  146                                 32 (21.9)    0.542   20   4 (20.0)    44   12 (27.3)   0.755   1.026 (0.443--2.377)    0.952

Mantel--Haenszel (adjusted) common odds ratio estimate. PTB, pulmonary tuberculosis; DM, diabetes mellitus; OR, odds ratio; CI, confidence interval; WBC, white blood cell; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AFB, acid-fast bacilli.

###### 

Management and treatment outcomes of new cases of culture-positive pulmonary tuberculosis with and without diabetes mellitus after adjustment for age

  Characteristic               PTB patients \< 50 years   PTB patients ≥ 50 years   DM vs. non-DM (all ages)                                                                                                                          
  ---------------------------- -------------------------- ------------------------- -------------------------- ---------------------- ------- ---- ---------------------- ---- ---------------------- ------- ----------------------- -------
  **Management**                                                                                                                                                                                                                      
   Standard regimen                                                                                                                                                                                                                   
    Intensive phase            17                         17 (100)                  146                        144 (98.6)             1.000   20   18 (90.0)              44   44 (100)               0.094   0.152 (0.013--1.722)    0.128
    Continuation phase         16                         16 (100)                  130                        127 (97.7)             1.000   19   16 (84.2)              41   41 (100)               0.028   0.160 (0.023--1.132)    0.066
   Duration, median (IQR)                                                                                                                                                                                                             
    Intensive phase, days      17                         64.0 (56.5--70.0)         146                        62.0 (54.0--73.5)      0.499   19   57.0 (51.0--83.0)      44   58.0 (17.8--72.0)      0.595   −                       −
    Continuation phase, days   16                         62.0 (54.0--73.5)         126                        119.0 (112.0--140.0)   0.387   17   121.0 (115.0--144.5)   41   124.0 (115.0--176.5)   0.533   −                       −
   Non-adherence                                                                                                                                                                                                                      
    Intensive phase            17                         2 (11.8)                  144                        19 (13.2)              1.000   19   4 (21.1)               44   5 (11.4)               0.434   1.361 (0.490--3.782)    0.555
    Continuation phase         16                         8 (50.0)                  130                        51 (39.2)              0.577   16   2 (12.5)               40   11 (27.5)              0.308   0.968 (0.418--2.242)    0.939
   Adverse drug events                                                                                                                                                                                                                
    Intensive phase            16                         12 (75.0)                 123                        76 (61.8)              0.450   16   14 (87.5)              35   24 (68.6)              0.185   2.262 (0.867--5.906)    0.095
    Continuation phase         3                          2 (66.7)                  57                         26 (45.6)              0.594   7    6 (85.7)               18   12 (66.7)              0.626   2.708 (0.501--14.649)   0.247
  **Treatment outcome**                                                                                                                                                                                                               
   Sputum-culture conversion                                                                                                                                                                                                          
    At month 2                 16                         14 (87.5)                 133                        113 (85.0)             1.000   18   15 (83.3)              41   33 (80.5)              1.000   1.225 (0.422--3.552)    0.709
    At month 5                 14                         12 (85.7)                 125                        122 (97.6)             0.079   18   18 (100)               40   39 (97.5)              1.000   0.324 (0.058--1.809)    0.199
   Treatment success           17                         14 (82.4)                 146                        118 (80.8)             1.000   20   16 (80.0)              44   38 (86.4)              0.712   0.859 (0.335--2.201)    0.751
    Cured                                                 12 (85.7)                                            88 (74.6)                           9 (56.3)                    28 (73.7)                                              
    Treatment completed                                   2 (14.3)                                             30 (25.4)                           7 (43.7)                    10 (26.3)                                              
   Death                       17                         0                         142                        3 (2.1)                1.000   20   2 (10.0)               44   1 (2.3)                0.228   2.232 (0.322--15.454)   0.416

Mantel--Haenszel (adjusted) common odds ratio estimate. PTB, pulmonary tuberculosis; DM, diabetes mellitus; OR, odds ratio; CI, confidence interval; IQR, interquartile range.

Discussion
==========

Tuberculosis is an infectious disease caused by the bacillus *M. tuberculosis*, which typically affects the lungs [@b2]. The burden of TB is highest in Asia, particularly in Southeast Asia and the Western Pacific region, where TB cases account for 60% of the cases reported worldwide. A recent study ranked Thailand, a Southeast Asian nation, 18th in a list of countries experiencing the highest incidence of TB [@b2]. Among the major risk factors for developing TB, which include contraction of immunodeficiency diseases, such as HIV or AIDS; poverty; illiteracy; smoking; and development of DM [@b2],[@b24], the last has been gradually increasing worldwide, especially in Southeast Asia [@b4], raising concern regarding TB and DM as comorbid conditions [@b7].

Despite knowledge of the concurrent increase in TB and DM incidence, collection of data regarding the characteristics of TB patients with DM has been limited to the incidence of DM in TB patients and the differences between the clinical and laboratory parameters, MDR-TB incidence and treatment outcomes of TB patients with and without DM. Previous studies have reported that patients experiencing different degrees of TB infection severity with HIV coinfection were 21--34 times at higher risk of developing active TB, leading to increased risk of death [@b25]. In order to clarify the role of DM in the treatment and management of TB patients, no patients with HIV coinfection were included in the current prospective study, which aimed to determine the proportion of newly diagnosed cases of PTB presenting with DM at two hospitals in Thailand and compare clinical and laboratory parameters, drug susceptibility and treatment outcomes in PTB patients with DM and without DM.

Among the 227 new cases of culture-positive PTB identified, 16.3% were found to have DM, a percentage similar to that found in other tropical countries [@b2]. Among the PTB patients with DM, 70.3% had been diagnosed with DM prior to PTB diagnosis and 29.7% had developed DM at PTB diagnosis. While no significant differences were found between PTB patients with DM and PTB patients without DM regarding the majority of the baseline characteristics and clinical parameters examined, PTB patients with DM were found to be significantly older and have a significantly lower level of education, which accorded with previous reports of advanced age and lower level of education as risk factors for DM [@b4],[@b26]. After adjustment for age as a confounding factor, a significantly higher proportion of PTB patients without DM was found to have presented with the symptom of cough, whereas a significantly higher proportion of PTB patients with DM was found to have presented with anorexia and haemoptysis, findings similar to those of a previous study reporting that the clinical presentation of PTB differs little between patients with and without DM [@b27]. However, other studies have also reported differences in the results of chest radiography in PTB patients with and without DM because of differences in duration of illness and host immune status [@b7],[@b14],[@b28]--[@b34]. While some studies have reported a higher incidence of multi-lobar disease and multiple cavities on chest radiography in PTB patients with DM [@b14],[@b28],[@b30],[@b32]--[@b34], other studies have reported no differences in chest radiography between PTB patients with and without DM [@b29],[@b31]. The current study, which found no significant differences in the chest radiography results of PTB patients with and without DM, accords with the latter group of studies.

Previous studies have reported sputum-culture conversion duration of 42--67 days in PTB patients with DM, compared with a shorter duration of 37--39 days in PTB patients without DM [@b13],[@b35],[@b36]. On the other hand, previous studies have also reported that the sputum-culture conversion rate at 2 months after anti-TB therapy did not significantly differ in PTB patients with DM and without DM (82--86% and 90--99%, respectively) [@b23],[@b37], a finding in accordance with the results of this study. While similar proportions of PTB patients with DM and PTB patients without DM were observed to have a high mycobacterium burden in sputum in this study, it is probable that the prolonged sputum-culture conversion duration in PTB patients with DM was because of factors other than high mycobacterium burden in sputum. Previous studies have hypothesised that the lower level of rifampicin observed in the serum of TB patients with DM may have been because of decreased absorption and protein binding of the drug, which could have led to increased sputum-culture conversion duration, MDR-TB rate, treatment failure rate and/or mortality in these patients [@b7],[@b15],[@b38],[@b39].

Previous studies have also raised concerns regarding drug interactions between anti-TB and hypoglycaemic drugs, with one reporting a decrease in serum concentrations of sulphonylurea and thiazolidinedione with simultaneous administration of rifampicin. In this study, similar adverse drug events were observed in PTB patients with and without DM, including rash (45.4%), peripheral neuropathy (36.6%), visual disturbance (20.0%), fatigue (10.7%), cholestasis (2.9%) and hepatitis (2.0%). In our clinical practice, pyridoxine is commonly prescribed to prevent peripheral neuropathy in PTB patients at risk of developing malnutrition because of anorexia or ageing. MDR-TB incidence, treatment success rate and mortality were likewise found to be similar for PTB patients with and without DM. After completion of treatment, PTB patients with DM who had experienced treatment success did not experience relapse of PTB during the 12-month follow-up period, a finding that contrasts with those of previous studies reporting a higher risk of MDR-TB, mortality, treatment failure and relapse for PTB patients with DM [@b11]--[@b15],[@b40]. This discrepancy may have been because of the inclusion of only newly diagnosed PTB patients and exclusion of patients with HIV coinfection in this study. Another discrepancy in findings was the identification of a treatment success rate of approximately 80% for both PTB patients with DM and PTB patients without DM, a percentage slightly lower than that (88%) reported by previous studies conducted in other high TB-burden countries [@b2], which may have been because of higher incidence of non-adherence during the intensive and continuation phases.

In conclusion, the incidence of DM in the newly diagnosed PTB patients examined in this study was 16.3%, of whom 70.3% had been diagnosed with DM prior to PTB diagnosis and 29.7% had developed DM at PTB diagnosis. The majority of clinical and laboratory parameters, as well as the MDR-TB incidence and treatment outcomes, were similar in PTB patients with DM and those without DM. These findings, particularly that 30% of PTB patients with DM may have developed DM at PTB diagnosis and that many patients later diagnosed with DM presented with a high plasma glucose level during PTB diagnosis, suggest that plasma glucose levels should be monitored during PTB diagnosis. The findings also suggest that similar treatment for newly diagnosed PTB patients with DM and without DM should be provided in high TB-burden countries.
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